Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Knockdown of USP28 enhances the radiosensitivity of esophageal cancer cells via the c‐Myc/hypoxia‐inducible factor‐1 alpha pathway

View through CrossRef
AbstractAcquired radioresistance is a major clinical obstacle in the treatment of esophageal cancer (EC). Ubiquitin‐specific protease 28 (USP28) has been implicated in tumor growth in various cancer types. However, the role of USP28 and its underlying mechanisms of radioresistance in EC remain unknown. In the current study, we found that USP28 and c‐Myc levels were upregulated in EC tissues and EC cell lines. The mRNA expression levels of USP28 and c‐Myc were increased in the radioresistant human EC cell line (ECA109R) compared with those in ECA109 cells. In addition, the expression levels of USP28 and c‐Myc were increased with increase in culture time after irradiation. Meanwhile, overexpression of USP28 decreased the radiosensitivity of ECA109 cells. In contrast, USP28 knockdown enhanced the radiosensitivity of ECA109R cells. Moreover, USP28 positively regulated the protein level of c‐Myc, and c‐Myc negatively regulated the radiosensitivity of ECA109 and ECA109R cells. Furthermore, c‐Myc reversed the inhibitory effect of USP28 on the radiosensitivity of EC cells. Additionally, c‐Myc enhanced the accumulation of hypoxia‐inducible factor‐1 alpha (HIF‐1α) at the posttranscriptional level, and the reinforcing effect of c‐Myc silencing on the radiosensitivity of EC cells could be reversed by HIF‐1α overexpression. Besides, knockdown of USP28 blocked the effect of c‐Myc on activation of ataxia telangiectasia‐mutated/ataxia telangiectasia and Rad3‐related DNA damage checkpoint after irradiation. In conclusion, knockdown of USP28 enhanced the radiosensitivity of EC cells by destabilizing c‐Myc and enhancing the accumulation of HIF‐1α. Therefore, USP28 may serve as a novel therapeutic target to overcome EC radioresistance.
Title: Knockdown of USP28 enhances the radiosensitivity of esophageal cancer cells via the c‐Myc/hypoxia‐inducible factor‐1 alpha pathway
Description:
AbstractAcquired radioresistance is a major clinical obstacle in the treatment of esophageal cancer (EC).
Ubiquitin‐specific protease 28 (USP28) has been implicated in tumor growth in various cancer types.
However, the role of USP28 and its underlying mechanisms of radioresistance in EC remain unknown.
In the current study, we found that USP28 and c‐Myc levels were upregulated in EC tissues and EC cell lines.
The mRNA expression levels of USP28 and c‐Myc were increased in the radioresistant human EC cell line (ECA109R) compared with those in ECA109 cells.
In addition, the expression levels of USP28 and c‐Myc were increased with increase in culture time after irradiation.
Meanwhile, overexpression of USP28 decreased the radiosensitivity of ECA109 cells.
In contrast, USP28 knockdown enhanced the radiosensitivity of ECA109R cells.
Moreover, USP28 positively regulated the protein level of c‐Myc, and c‐Myc negatively regulated the radiosensitivity of ECA109 and ECA109R cells.
Furthermore, c‐Myc reversed the inhibitory effect of USP28 on the radiosensitivity of EC cells.
Additionally, c‐Myc enhanced the accumulation of hypoxia‐inducible factor‐1 alpha (HIF‐1α) at the posttranscriptional level, and the reinforcing effect of c‐Myc silencing on the radiosensitivity of EC cells could be reversed by HIF‐1α overexpression.
Besides, knockdown of USP28 blocked the effect of c‐Myc on activation of ataxia telangiectasia‐mutated/ataxia telangiectasia and Rad3‐related DNA damage checkpoint after irradiation.
In conclusion, knockdown of USP28 enhanced the radiosensitivity of EC cells by destabilizing c‐Myc and enhancing the accumulation of HIF‐1α.
Therefore, USP28 may serve as a novel therapeutic target to overcome EC radioresistance.

Related Results

L᾽«unilinguisme» officiel de Constantinople byzantine (VIIe-XIIe s.)
L᾽«unilinguisme» officiel de Constantinople byzantine (VIIe-XIIe s.)
&nbsp; <p>&Nu;ί&kappa;&omicron;&sigmaf; &Omicron;&iota;&kappa;&omicron;&nu;&omicron;&mu;ί&delta;&eta;&sigmaf;</...
North Syrian Mortaria and Other Late Roman Personal and Utility Objects Bearing Inscriptions of Good Luck
North Syrian Mortaria and Other Late Roman Personal and Utility Objects Bearing Inscriptions of Good Luck
<span style="font-size: 11pt; color: black; font-family: 'Times New Roman','serif'">&Pi;&Eta;&Lambda;&Iota;&Nu;&Alpha; &Iota;&Gamma;&Delta...
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphoma
Mantle cell lymphoma (MCL) with MYC rearrangement (MYC-R) is rare and little is known about the importance of MYC extra copies (EC) in the absence of MYC-R in MCL patients. This st...
Improving immunotherapy in high-grade B-cell lymphoma
Improving immunotherapy in high-grade B-cell lymphoma
MYC is a transcription factor that upon deregulation acts as an oncogene. Cancer patients with MYC overexpression face significant worse outcomes to treatment with (immuno)chemothe...
Un manoscritto equivocato del copista santo Theophilos († 1548)
Un manoscritto equivocato del copista santo Theophilos († 1548)
<p><font size="3"><span class="A1"><span style="font-family: 'Times New Roman','serif'">&Epsilon;&Nu;&Alpha; &Lambda;&Alpha;&Nu;&...
Abstract 5833: Targeting the transcription co-activator TAZ inhibits MYC-driven medulloblastoma
Abstract 5833: Targeting the transcription co-activator TAZ inhibits MYC-driven medulloblastoma
Abstract Medulloblastoma (MB), the most common malignant pediatric brain tumor, results in significant neurological, intellectual and physical disability or death. F...
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract 1872: Targeting MYC-driven medulloblastoma using inhibitors of glutamine metabolism.
Abstract Medulloblastoma is the most common malignant brain tumor in children. Currently, treatment consists of surgical resection, chemotherapy, and whole brain and...

Back to Top